Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study.

ABSTRACT:

Background

Epidermolysis bullosa (EB) patient anecdotes and case reports indicate that cannabinoid-based medicines (CBMs) may alleviate pain and pruritus and improve wound healing. CBM use has not been characterized in the EB patient population.

Objectives

To evaluate CBM use among EB patients, including CBM types, effects on symptoms (e.g., pain and pruritus), disease process (e.g., blistering, wounds, and inflammation), well-being (e.g., sleep, appetite) and concomitant medications.

Methods

English-speaking EB patients or caregivers completed an online international, anonymous, cross-sectional survey regarding CBM use. Respondents reported the types of CBMs, subsequent effects including perceived EB symptom alteration, changes in medication use, and side effects.

SUBMITTER: Schrader NHB 

PROVIDER: S-EPMC8419930 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature